Literature DB >> 11221163

Combined oral and parenteral iron chelation in beta thalassaemia major.

K Balveer1, K Pyar, B Wonke.   

Abstract

Thalassaemics in Malaysia are poorly chelated because desferrioxamine is too expensive and cumbersome for long term compliance. The efficacy and tolerability of the oral chelator deferiprone, and the effects of using a combination therapy in our patients were studied. Ten patients completed the study and the mean serum ferritin reduced from 7066.11 ug/L (2577-12,896 ug/L) to 3242.24 ug/L (955-6120 ug/L). The liver iron concentration did not show a significant drop (19.6 vs 18.2 mg/g dry weight) although 3 patients showed reductions ranging from 30-40%. Concomitant use of desferrioxamine increased the urinary excretion from a mean of 13.66 mg/day to 27.38 mg/day. Main side effects seen were nausea and rashes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11221163

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  4 in total

Review 1.  Beta-thalassemia.

Authors:  Renzo Galanello; Raffaella Origa
Journal:  Orphanet J Rare Dis       Date:  2010-05-21       Impact factor: 4.123

2.  Deferiprone-induced agranulocytosis: 20 years of clinical observations.

Authors:  Fernando Tricta; Jack Uetrecht; Renzo Galanello; John Connelly; Anna Rozova; Michael Spino; Jan Palmblad
Journal:  Am J Hematol       Date:  2016-08-04       Impact factor: 10.047

3.  Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Authors:  Nancy F Olivieri; Amir Sabouhanian; Brenda L Gallie
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

4.  Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Authors:  Renzo Galanello
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.